Asia Tumbles, Tesla...
Health Care: Drugs
Immunomedics Inc. (IMMU: NASDAQ)
$3.28 0.14 | 4.46%
05/23/13 - 04:00 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 32.73M | 14.71M | 60.93M | 30.02M |
| Cost of Sales | 427.04K | 419.35K | 45.68M | 24.65M |
| Gross Operating Profit | 32.31M | 14.29M | 15.25M | 5.37M |
| Selling, General, and Administrative Expenses | 6.61M | 7.94M | 6.18M | 5.77M |
| Research & Development | 24.82M | 25.37M | 19.85M | 21.48M |
| Operating Income before D & A (EBITDA) | 874.17K | -19.02M | -10.78M | -21.88M |
| Depreciation & Amortization | 1.50M | 1.36M | -44.72M | -24.37M |
| Interest Income | 18.76K | 519.01K | 788.86K | 1.25M |
| Other Income - Net | 13.23K | 3.37M | 1.05M | -2.35M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -590.62K | -16.49M | 35.77M | 1.38M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 6.50K |
| Pre-Tax Income | -590.62K | -16.49M | 35.77M | 1.37M |
| Income Taxes | 209.78K | 109.88K | -1.23M | -900.39K |
| Minority Interest | -113.57K | -173.99K | 0.00 | 0.00 |
| Net Income From Continuing Operations | 809.95K | -15.07M | 37.00M | 2.27M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 809.95K | -15.07M | 37.00M | 2.27M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 809.95K | -15.07M | 37.00M | 2.27M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
809.95K | -15.07M | 37.00M | 2.27M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 809.95K | -15.07M | 37.00M | 2.27M |
| Basic EPS from Continuing Ops. | 0.01 | -0.20 | 0.49 | 0.03 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.01 | -0.20 | 0.49 | 0.03 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.01 | -0.20 | 0.49 | 0.03 |
| Basic Normalized Net Income/Share | 0.01 | -0.20 | 0.49 | 0.03 |
| EPS fr Continuing Ops. | 0.01 | -0.20 | 0.49 | 0.03 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.01 | -0.20 | 0.49 | 0.03 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.01 | -0.20 | 0.49 | 0.03 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.01 | -0.20 | 0.49 | 0.03 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with IMMU
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks to Watch Under $5
- Usertoms
- UserASCO 2010
- UserPortfolioRadical1
- UserPART 7 JPMorgan 28th Annual...
- Userinvestone
- Usermchish Portfolio 1
- UserASCO 2009 Nymph's Watch List.
Latest IMMU Headlines from TheStreet
- Immunomedics Develops T-Cell Redirecting Bispecific Antibodies As Potential Therapeutics For Solid And Liquid Tumors 04.10.13 | 08:04 am
- Immunomedics Reports First Results Of Labetuzumab-SN-38 In Colorectal Cancer 04.09.13 | 08:04 am
- Immunomedics Creates Novel Antibody-Cytokine Conjugates For Cancer Therapy 04.08.13 | 04:04 pm
- Immunomedics Announces Clivatuzumab-Based Blood Test Can Differentiate Between Pancreatic Cancer And Chronic Pancreatitis 04.08.13 | 01:04 pm
- Immunomedics Settles Finra Arbitration Proceedings Relating To Its Prior Investment In Certain Securities 04.01.13 | 05:04 pm
- Immunomedics Announces Presentations At The 2013 Annual Meeting Of The American Association For Cancer Research 04.01.13 | 08:04 am
- Immunomedics Announces Closing Of Public Offering And Full Exercise Of Overallotment Option By Underwriters 02.27.13 | 04:02 pm
- Immunomedics To Present At Cowen And Company 33rd Annual Health Care Conference 02.25.13 | 08:02 am
- Immunomedics Prices $14.0 Million Public Offering Of Common Stock 02.22.13 | 09:02 am
- Immunomedics Announces Proposed Public Offering Of Common Stock 02.21.13 | 04:02 pm
Press Releases for IMMU
Partner Headlines for IMMU
- Immunomedics Earnings: Your Sneak Peek to the Big Announcement - Wall St. Cheat Sheet 05.08.13 | 03:05 am
- Immunomedics Reports Clinically Meaningful Improvements for Lupus Patients Treated with Epratuzumab - Benzinga 11.13.12 | 09:11 am
- Merck Facing Too Much Competition In HIV Drug Push - Seeking Alpha 08.22.12 | 09:08 am
- CNS Cure Priority for UCB & Partner - Analyst Blog - Zacks 01.13.12 | 10:01 am
- Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune - Benzinga 12.12.11 | 01:12 pm
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography - Benzinga 06.08.11 | 04:06 pm
- UCB's Progress On-Track - Analyst Blog - Zacks 01.12.11 | 09:01 am
- Monoclonal Antibody Companies Command Premiums - Seeking Alpha 07.12.10 | 08:07 am
- Zacks Analyst Blog Highlights: Immunomedics, Human Genome, GlaxoSmithKline, CNOOC and Devon Energy - Press Releases - Zacks 06.22.10 | 09:06 am
